Other · developed by GRI Bio Operations
GRI-0621 is an investigational drug studied in Psoriatic Arthritis, Diabetes, Type I, Chronic Obstructive Pulmonary Disease (COPD).
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06671483 | Phase 3 | Psoriatic Arthritis | Active not recruiting | TAK |
| NCT05298644 | Phase 2/3 | SARS-CoV-2 Infection | Withdrawn | VALN |
| NCT00308308 | Phase 3 | Diabetes, Type I | Completed | MNKD |
| NCT02949375 | Phase 2 | Chronic Liver Disease | Terminated | GRI |
| NCT01921712 | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | PULM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Psoriatic ArthritisChronic Liver DiseaseChronic Obstructive Pulmonary Disease (COPD)Diabetes, Type ISARS-CoV-2 Infection
Updated Oct 25, 2026. Something wrong or missing? Report it on the GRI page.
See GRI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GRI catalysts and pipeline →